Targeting the mitogen-activated protein kinase cascade to treat cancer

By J. Sebolt-Leopold, R. Herrera. Nature Reviews. Cancer, 2004

1,166 citations recorded by the source corpus.

Subfields: Molecular Biology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/1b5d0341c9b6ea4bbf958bf7c590f11e8175d6c9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. C. Der
2. N. Hynes
3. P. Roberts
4. J. Asara
5. Lewis C. Cantley
6. A. Nebreda
7. S. Hagan
8. Olivier Elemento

In Pathology and Forensic Medicine

1. C. Der
2. P. Roberts
3. N. Hynes
4. H. Lane

Citations in the corpus

• Signal integration by JNK and p38 MAPK pathways in cancer development (2009, background): “The ERK1 and ERK2 MAPKs are activated by mitogens and were found to be upregulated in human tumours; this finding has led to the development of inhibitors of this pathway for cancer therapeutic”
• Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth (2015, background): “Pharmacological inhibitors targeting the MAPK (Sebolt-Leopold and Herrera, 2004) and PI3K (Luo Mo et al., 2003) pathways have been developed and shown to have antitumor activity, and there are numerous clinical trials testing such inhibitors for the treatment of a broad spectrum of cancers (Liu et…”
• MAP kinase signalling pathways in cancer (2007, background): “Activating mutations in K-Ras and N-Ras occur in varying frequencies in different types of cancer and have been recently reviewed (Downward, 2003; Sebolt-Leopold and Herrera, 2004).”
• ERBB receptors and cancer: the complexity of targeted inhibitors (2005, methodology): “Furthermore, targeting the MAPK pathway (reviewed in Ref”
• Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH (2015, background): “aaa5004 Activating KRAS and BRAF mutations are found in approximately 40% and 10% of human colorectal cancers (CRCs), respectively (1).”
• Polyphenols and Human Health: Prevention of Disease and Mechanisms of Action (2010, background): “The MAPK signaling pathway has long been viewed as an attractive pathway for anticancer therapies, based on its central role in regulating the growth and survival of cells from a broad spectrum of human cancers [64], and its role in the transcriptional and post-transcriptional activation of COX-2 [6”
• A review: benefit and bioactive properties of olive (Olea europaea L.) leaves (2016, background): “Olive leaves comprise about 10 % of the weight of olives collected for olive oil extraction [8], and most of them are used as animal feed or simply burned with excess branches gathered from pruning [9, 10].”
• Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer (2007, background): “Unlike the considerable volume of preclinical studies that utilized highly specific inhibitors of MEK1/2 (PD98059, U0126 and CI-1040/PD184352) or p38 (SB203580 and SB 202190) (Davies et al., 2000), the preclinical observations made with the SP600125 JNK inhibitor are likely to be less informative re”
• CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway (2008, background): “Specifically, the Akt/PKB pathway and members of the Bcl-2 survival family have been studied extensively and shown to play an important anti-apoptotic role in many cancers (Nicholson and Anderson, 2002; Sebolt-Leopold and Herrera, 2004).”